Eric Pham, PhD

Eric Pham joined Avego BioScience Capital in 2024 and is a Managing Director. Previously, he was a Vice President at Blue Owl Healthcare Opportunities (formerly known as Cowen Healthcare Investments), where he was an investor in mid-to-late stage private and public biotechnology companies developing novel therapies for patients with high unmet need. His key investments while at Blue Owl included Escient Pharmaceuticals (acquired by Incyte), Prometheus Biosciences (acquired by Merck), and Akouos (acquired by Lilly).

Prior to Blue Owl, he was a Senior Analyst on the Investments Team at Roivant Sciences, where he focused on identifying, evaluating, and acquiring promising therapeutic programs for further development.

Eric received his Ph.D. in Molecular and Cell Biology from University of Houston and B.A. in Molecular and Cell Biology from University of California, Berkeley.